CAS: 426219-51-4; 6,7-Dihydroimidazo[1,5-A]Pyridin-8(5H)-One
该化合物是一个环状的环状的热循环有机化合物,其特点是有线虫环和环.该化合物具有双环结构,具有独特的化学特性.由于其环状结构中存在氮原子,因此极地溶剂中通常具有中等溶解性,可进行氢联结.该化合物可能显示生物活动,使其对医药化学感兴趣,特别是制药业.其分子结构允许与生物目标进行可能的相互作用,可在药物设计中加以探讨.此外,8位置中的碳基类群体的存在可影响其再活动性和稳定性.与许多热循环一样,氮原子的电子特性可影响化合物的酸性和基本性,这对于其在各种化学反应中的再活动十分重要.
- 英文名称6,7-Dihydroimidazo[1,5-A]Pyridin-8(5H)-One
- 中文名称6,7-二氢咪唑并[1,5-a]吡啶-8(5H)-酮
- IUPAC名称6,7-dihydroimidazo[1,5-a]pyridin-8(5H)-one
- 其它别名6,7-二氢-5H-咪唑[1,5-A]吡啶-8-酮; Imidazo[1,5-A]Pyridin-8(5H)-One, 6,7-Dihydro- (9Ci)
- CAS编号426219-51-4
- MFCD编号:MFCD11110652
- EINECS号:892-668-2
- 分子式:C7H8N2O分子量:136.15
- 产品CID: 1439120
- 产品分类有机原料→分子砌块→芳杂环类化合物→咪唑类化合物
相似化合物
38666-30-7 2703754-49-6 426219-43-4物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
CAS号38666-30-7 5,6,7,8-四氢咪唑并[1...合成工艺路线路线简述
📜5,6,7,8-四氢-咪唑并[1,5-A]吡啶置于potassium Permanganate,盐酸体系中,用 乙腈,水 作为反应溶剂,化学反应 16.03H,以75%的收率获得产物6,7-二氢咪唑并[1,5-A]吡啶-8(5H)-酮
参考文献:Process For Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One
标题:Process For Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One
摘要:6,7-二氢-5H-咪唑[1,5-A]吡啶-8-酮(i)可以通过以下方法高产率地得到:1)从适当保护的c-(3-羟基吡啶-2-基)甲胺开始,其胺基转化为甲酰胺,然后环化为咪唑[1,5-A]吡啶,并氢化为6,7-二氢-5H-咪唑[1,5-A]吡啶-8-酮,适当保护的c-(3-羟基吡啶-2-基)甲胺可以通过两步法从商业可得的3-羟基-2-氰基吡啶[932-35-4]制备,或者通过三步法从商业可得的2-羟甲基吡啶-3-醇[14173-30-9]制备;2)从n,N-二甲基-2-(三烷基硅基)咪唑-1-磺酰胺通过锂化和随后与适当保护的4-羟基丁醛反应,然后氧化二级醇,酸诱导去保护咪唑和去保护醇官能团,制备4-羟基-1-(1H-咪唑-4-基)丁酮,这是合成6,7-二氢-5H-咪唑[1,5-A]吡啶-8-酮(式i)的中间体,如wo 2002/040484中所述;3)从5,6,7,8-四氢咪唑[1,5-A]吡啶[38666-30-7]开始进行氧化的方法.
海关参考信息
- 2912110000-甲醛
2912120000-乙醛
2914190090-其他无环酮 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2009118512-A1
优先权日:2006-03-31
标 题:Process for Preparing 6,7-Dihydro-5H-Imidazo[1,5-A]Pyridin-8-One
发明人：MARTIN PIERRE; BOUDIER ANDREAS; QUIRMBACH MICHAEL; MAH ROBERT; JOTTERAND NATHALIE
权利人:MARTIN PIERRE; BOUDIER ANDREAS; QUIRMBACH MICHAEL; MAH ROBERT; JOTTERAND NATHALIE
摘要:6,7-Dihydro-5H-imidazo[1,5-a]pyridin-8-one (I), is obtainable in high yields by: 1) a process which proceeds from a suitably protected C-(3-hydroxypyridin-2-yl)methylamine whose amine is converted to the formamide which is then cyclized to the imidazo[1,5-a]pyridine and hydrogenated to the 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one, and suitably protected C-(3-hydroxypyridin-2-yl)methylamines can be prepared either in 2 steps proceeding from commercially available 3-hydroxy-2-cyanopyridine [932-35-4] or in 3 steps proceeding from commercially available 2-hydroxymethylpyridin-3-ol [14173-30-9]; 2) a process for preparing 4-hydroxy-1-(1H-imidazol-4-yl)butan-1-one, an intermediate from the synthesis of 6,7-dihydro-5H-imidazo[1,5-a]pyridin-8-one (formula I), as described in WO 2002/040484, proceeding from N,N-dimethyl-2-(trialkylsilanyl)imidazole-1-sulphonamide by lithiation and subsequent reaction with a suitably protected 4-hydroxybutyraldehyde, followed by oxidation of the secondary alcohol, acid-induced deprotection of the imidazole and deprotection of the alcohol functionality; 3) a process which proceeds from 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine [38666-30-7], which is oxidized.
